VC investors from China and Hong Kong have backed the first close of a $21 million Series B round for Cambridge-based Life Science company CN Bio. Beijing-based Bayland Capital and founding shareholder CN Innovations Holdings Ltd from Hong Kong are to invest $10m and $5.5m, respectively. Other serial backers have reinvested.
CN Bio Raises $21 Million USD in First Close of Series B Investment Round finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Bayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10 M and $5.5 M, respectively. Investment will expand product development and scaling of the organization to meet increased demand for Organ-on-a-Chip (OOC) solutions.